Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus Type 1 Infection
Article information
J Korean Med Assoc. 2007;50(4):316-323
Publication date (electronic) : 2007 April 30
doi :
https://doi.org/10.5124/jkma.2007.50.4.316
Abstract
It has now been 20 years since the first demonstration that antiretroviral drug, azidothymidine, not only reduce human immunodeficiency virus type 1(HIV-1) replication but also improve clinical outcome. Antiretroviral therapy for treatment of HIV-1 infection has improved steadily since the introduction of combination therapy in 1996. With the advancement of antiretroviral therapy, the mortality of AIDS patients has markedly improved. Now, more than 20 anti-HIV drugs have been approved, providing more convenient dosing schedule and improved safety profiles. Despite these advances, suppression of HIV-1 replication would not sufficient to eradicate HIV-1 infection. This means that once antiretroviral therapy is initiated, patients can expect to be taking it for the rest of their lives. And long-term drug toxicities, development of drug resistant HIV-1, treatment cost have been emerging as new challenges for the treatment of HIV-1 infection. As the life expectancy of HIV-1 patients have been increased, chronic illnesses such as cardiovascular diseases, chronic liver diseases, and malignancies have emerged as major cause of mortality and morbidities of HIV-1 patients. Therefore, comprehensive care and team approaches have becoming increasingly important for the care of HIV-1 patients.
References
1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT. AZT Collaborative Working Group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1987. 317185–191.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection. N Engl J Med 1998. 338853–860.
3. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS Assessed Mar 10, 2007. at http://www.aidsinfo.nih.gov.
4. Oh MD. Korean Society of Infectious Diseases. Treatment of HIV Infection. Infectious Diseases 2007. 1st edth ed. Seoul: Koonja Publishing Co; 1203–1208.
5. Ho DD, Neumann AU, Perelson AS. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995. 373123–126.
6. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996. 2721167–1170.
7. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002. 360119–129.
8. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC. AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003. 3492304–2315.
9. Lampe S, Gatell J, Staszewski S, et al. Trends over time in initial virological failure of first HAART, 1996 to 2002: a joint cohort analysis of 4143 subjects. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections 2005. February 22-25, 2005; Boston, Massachusetts. Abstract 593.
10. Murphy R, da Silva B, McMillan F, et al. Seven-year follow-up of a lopinavir/ritonavir (LPV/R)-based regimen in antire-troviralnaive subjects. Program and abstracts of the 10th European AIDS Conference 2005. November 17-20; Dublin, Ireland. Abstract PE7.9/3.
11. Tashima K, Staszewski S, Nelson M, et al. Durable viral suppression on EFV-based HAART: 168 weeks of follow-up. Pro-gram and abstracts of the XV International AIDS Conference 2004. July 11-16; Bangkok, Thailand. Abstract TuPeB4547.
12. Siciliano JD, Kajadas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Med 2003. 9727–728.
13. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005. 366549–555.
14. Schooley RT, Mellors JW. No Cure Yet for HIV-1, But Therapeutic Research Presses On. J Infect Dis 2007. 195770–772.
15. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR. Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006. 41194–200.
16. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995~2005. Ann Intern Med 2007. 14687–95.
17. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, Huang LY, Chen MY, Hwang JS, Wang JD, Chuang CY. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 2007. 10097–105.
18. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006. 4327–34.
19. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, Heptonstall J, Ippolito G, Lot F, McKibben PS, Bell DM. Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997. 3371485–1490.
20. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005. 09. 30. 54(RR-9)1–17.
21. Almeda J, Casabona J, Simon B, Gerard M, Rey D, Puro V, Thomas T. Euro-NONOPEP Project group. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveill 2004. 935–40.
22. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S. AIEDRP Network. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006. 194725–733.
Article information Continued
Copyright © 2007 Korean Medical Association
